PMID: 3709612Jan 1, 1986Paper

Pharmacokinetics of tenoxicam in patients with impaired renal function

European Journal of Clinical Pharmacology
F F HorberF J Frey

Abstract

The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5'OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5'OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5'OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure.

References

Aug 1, 1979·European Journal of Clinical Pharmacology·G CuisinaudJ Sassard
Jan 1, 1978·Scandinavian Journal of Rheumatology. Supplement·H StierlinA Colombi
Mar 1, 1979·British Journal of Clinical Pharmacology·R VerbeeckP J de Schepper
Dec 1, 1977·Kidney International·T P GibsonW A Briggs
Mar 1, 1975·Journal of the Experimental Analysis of Behavior·D Yager, M Romeskie
Jan 10, 1986·Journal of Chromatography·P HeizmannK Zinapold
Jan 1, 1985·European Journal of Clinical Pharmacology·R W BuryR F Moulds
Sep 1, 1972·Kidney International·H W Leber, G Schütterle
Jul 1, 1983·Clinical Pharmacokinetics·R K VerbeeckG R Loewen
May 29, 1980·The New England Journal of Medicine·L S Simon, J A Mills
Jan 1, 1981·Scandinavian Journal of Rheumatology·G Stafanger Sørensen
Oct 1, 1980·European Journal of Clinical Pharmacology·M AnttilaA Kasanen
Jan 1, 1981·Clinical Pharmacology and Therapeutics·H J RogersR G Spector

❮ Previous
Next ❯

Citations

Mar 1, 1990·Journal of Clinical Pharmacology·M P SchoerlinM Mayersohn
Jan 1, 1988·European Journal of Clinical Pharmacology·O G NilsenE Thue
Jan 1, 1992·European Journal of Clinical Pharmacology·M S al-GhamdiI S al-Saeed
Jan 1, 1989·European Journal of Drug Metabolism and Pharmacokinetics·C CrevoisierU C Dubach
Jan 1, 1989·Drug Metabolism Reviews·T F Woolf, L L Radulovic
Jan 1, 1990·Current Medical Research and Opinion·A C SchwarzerP M Brooks
Feb 13, 2014·Seminars in Dialysis·Sara N DavisonFrank Brennan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

British Journal of Rheumatology
J S DixonN Saunders
Baillière's Clinical Rheumatology
J H Turney, E H Cooper
Hand Surgery : an International Journal Devoted to Hand and Upper Limb Surgery and Related Research : Journal of the Asia-Pacific Federation of Societies for Surgery of the Hand
Aya YoshidaTomohide Motomura
© 2021 Meta ULC. All rights reserved